
Loading, please wait...

Loading, please wait...
Management of complex proximal humerus fractures in older adults remains controversial because bone quality, tuberosity involvement and rotator-cuff function all influence the result. In this prospective randomized trial, adults aged 80 years or older with displaced three- or four-part proximal humeral fractures were assigned to reverse shoulder arthroplasty or nonoperative treatment. The study directly addressed a clinically important question: whether replacing the joint can provide better pain relief and function than accepting fracture healing without surgery. The trial supports reverse arthroplasty as a reasonable option for carefully selected very elderly patients, particularly when fracture complexity and cuff dysfunction make fixation or reliable tuberosity healing difficult. At the same time, treatment should not be reduced to age alone. Surgical risk, pre-injury function, frailty, expectations and the feasibility of rehabilitation remain central to decision-making. The study is useful because it places reverse arthroplasty within a comparative framework rather than relying only on case series. For an orthopaedic surgeon, the practical takeaway is to consider reverse arthroplasty when the fracture pattern is unlikely to deliver predictable function with conservative care, while still individualising the decision according to patient biology and goals.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.

Management of complex proximal humerus fractures in older adults remains controversial because bone quality, tuberosity involvement and rotator-cuff function all influence the result. In this prospective randomized trial, adults aged 80 years or older with displaced three- or four-part proximal humeral fractures were assigned to reverse shoulder arthroplasty or nonoperative treatment. The study directly addressed a clinically important question: whether replacing the joint can provide better pain relief and function than accepting fracture healing without surgery. The trial supports reverse arthroplasty as a reasonable option for carefully selected very elderly patients, particularly when fracture complexity and cuff dysfunction make fixation or reliable tuberosity healing difficult. At the same time, treatment should not be reduced to age alone. Surgical risk, pre-injury function, frailty, expectations and the feasibility of rehabilitation remain central to decision-making. The study is useful because it places reverse arthroplasty within a comparative framework rather than relying only on case series. For an orthopaedic surgeon, the practical takeaway is to consider reverse arthroplasty when the fracture pattern is unlikely to deliver predictable function with conservative care, while still individualising the decision according to patient biology and goals.
Today

The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back

A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back

Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back

A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back

A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back